louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03666169: Receiving Genetic Information: A Quantitative Survey
Official title: The Public's Response to Receiving Genetic Information Via an Electronic Platform: A Quantitative Survey
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obesity
Lead sponsor: St Mary's University College
Sponsor class: OTHER
First posted: 2018-09-11
Enrollment: 370
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: UK citizens between the ages of 18 and 65 years

Brief summary: This study will evaluate the public's response to receiving genetic information via an electronic platform. It will comprise of an internet run quantitative survey.

Detailed description: There is currently a high prevalence of obesity in the UK. Diets personalised to an individual's genetics could help to reduce the prevalence. However, how the public will respond to this information is unknown. The use of technology is very common and could provide an accessible platform to communicate genetic results to the public. Therefore, this study will evaluate the public's response to receiving genetic information via an electronic platform.

This study will comprise of an internet run quantitative survey. The survey will be circulated using relevant websites, internet forums, emails and social media. Participants will be required to complete the survey once which will take around 10 minutes. The participants will not be required to complete the survey in a controlled setting, it may be complete wherever the participant feels comfortable. Data analysis will take place at St Mary's University.

Eligibility criteria: Inclusion Criteria:

UK citizens between the ages of 18 and 65 years

Primary outcomes:
measure: BMI against response.
timeFrame: October - November 2018
measure: Socioeconomic status versus response.
timeFrame: October - November 2018
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00890669: Treadmill Training and Quality of Life in Parkinson's Disease
Official title: Treadmill Walking Training With Additional Body Load Improves Quality of Life in Subjects With Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson's Disease
Keywords: treadmill training
body load
quality of life
Parkinson's disease
Motor Symptoms
Lead sponsor: Universidade Federal de Sao Carlos
Sponsor class: OTHER
First posted: 2009-04-30
Enrollment: 9
Sex: ALL
Minimum age (years): 51
Maximum age (years): 81
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Parkinson's disease (PD) causes motor and non-motor impairments that affect the quality of life of the subjects. The purpose was to assess the effects of treadmill walking training with additional body load on the quality of life and motor symptoms of the subjects with PD.

Methods: Nine subjects with PD, Hoehn and Yahr stages 2 through 3, not demented and with capability to ambulate independently voluntarily participate in this study. The training program was divided into three phases (A1-B-A2): treadmill training with additional body load (A1), control condition (conventional physical therapy group) (B) and treadmill training with load again (A2). Each phase lasted six weeks. The quality of life and motor symptoms were assessed by PDQ-39 and UPDRS, respectively. Both evaluations and training were performed during on-phase of the medication cycle.


Eligibility criteria: Inclusion Criteria:

* Hoehn and Yahr (H-Y) stages 2 through 3
* Absence of dementia (Mini-Mental Status Examination - MMSE, defined according to educational level)
* Capacity to ambulate independently for at least 10 meters

Exclusion Criteria:

* Change medication (dopaminergic) during the study period
* Use treadmill for at least six months prior to the study
* Other neurologic problems or musculoskeletal, cardiovascular and respiratory disease or uncorrected visual deficit that could represent risk and interfere in the accomplishment of the training

Primary outcomes:
measure: The quality of life was measured through Parkinson Disease Questionnaire (PDQ-39).
timeFrame: 4 times, once before treatment, and 3 after each treatment phase.
Secondary outcomes:
Other outcomes:
Locations:
city: São Carlos
country: Brazil
facility: Universidade Federal de São Carlos
state: SP
Study officials:
affiliation: Universidade Federal de Sao Carlos
name: Nadiesca T Filippin, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidade Federal de Sao Carlos
name: Rosana Mattioli, PhD
role: STUDY_CHAIR
affiliation: Universidade Federal de Sao Carlos
name: Paula H Lobo da Costa, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06029569: Rapamycin Coated Balloon Dilation Catheter for Arteriovenous Fistula
Official title: Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Rapamycin Coated Balloon Dilation Catheter in the Treatment of Dialysis Pathway Stenosis or Blockage in Hemodialysis Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: Shanghai Bomaian Medical Technology Co., Ltd
Sponsor class: INDUSTRY
First posted: 2023-09-08
Enrollment: 256
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Verify the effectiveness and safety of rapamycin coated balloon dilation catheter for the treatment of dialysis pathway stenosis or blockage lesions.

Detailed description: To verify the effectiveness and safety of the Rapamycin coated arteriovenous fistula balloon dilation catheter developed and produced by Shanghai Bomaian Medical Technology Co., Ltd. in the treatment of stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula in hemodialysis patients.

Eligibility criteria: Inclusion Criteria:

1. AVF has been established, with mature development and at least one successful completion of hemodialysis；
2. AVF has significant hemodynamic abnormalities；

exclusion criteria

1. The target lesion has undergone intervention treatment within 30 days；
2. An intravascular stent has been placed at any location along the vascular pathway；

Primary outcomes:
measure: 6-month target lesion primary patency rate
timeFrame: 6months
Secondary outcomes:
measure: Device success rate
timeFrame: The day of operation.
measure: Surgical success rate
timeFrame: 7Days
measure: Clinical success rate
timeFrame: 1year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06410469: A Novel Suturing Technique of Cystocele Treatment
Official title: A Novel Suturing Technique for Natural Tissue Repair in Cystocele Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cystocele
Keywords: anterior colporraphy
naturel tissue
suture technique
Lead sponsor: Ankara City Hospital Bilkent
Sponsor class: OTHER
First posted: 2024-05-13
Enrollment: 65
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women operated on for anterior wall prolapse in POP-Q

Brief summary: The rug weaving-like plication technique may offer a viable alternative for cystocele repair without mesh, utilizing natural tissue.

Detailed description: The aim of this study is to compare patients who underwent cystocele repair using the rug weaving plication technique, a natural tissue repair method implemented since 2022 for anterior prolapse, with those treated using conventional techniques.

The investigators retrospectively reviewed 33 patients who underwent anterior vaginal wall repair with the rug weaving-like plication technique and 32 patients who underwent surgery using conventional colporrhaphy. The investigators recorded demographic data and operative details of the patients. At the 6-month postoperative follow-up,the investigators assessed patients' complaints, Pelvic Organ Prolapse Quantification (POP-Q), Modified Oxford Scoring (MOS), and pelvic floor muscle strength. The investigators measured bladder wall thickness between the bladder and anterior vaginal wall using Transvaginal Ultrasonography (USG) and compared demographic data, operative details, and postoperative outcomes between the two groups.

Eligibility criteria: Inclusion Criteria: Patients operated on using the rug weaving plication technique

Exclusion Criteria:Patients operated on using the conventional anterior colporrhaphy

Primary outcomes:
measure: Pelvic Organ Prolapse Quantification (POP-Q)
timeFrame: Maximum 6 months
Secondary outcomes:
measure: Bladder thickness
timeFrame: Maximum 6 months
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara City Hospital
Study officials:
affiliation: Ankara City Hospital Bilkent
name: Rahime Bedir Findik
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00734669: Risk of Hypoglycemia in Type 2 Diabetes
Official title: Risk of Hypoglycemia in Type 2 Diabetes - Effects of Glibenclamide and Exercise on Cardiovascular, Hormonal, and Metabolic Parameters
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 2 Diabetes
Keywords: Diabetes
Hypoglycemia
Lead sponsor: University of Giessen
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2008-08-14
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Type 2 diabetes

Brief summary: The aim of this study is to establish the risk and frequency of non-symptomatic hypoglycemia in type 2 diabetes under previous therapy with glibenclamide. Participants will be monitored via a continuous glucose monitoring system in a standardized clinical setting during day and night time, implementing meals and exercise of moderate intensity performed in the postprandial state.

Detailed description: The day-to-day change of blood glucose is associated with the frequency of vascular complications and the quality of life of diabetic patients. In this study the frequency of hypoglycemic events in combination with postprandial hyperglycemia in type 2 diabetic patients on oral insulinotropic therapy will be observed. Using more sophisticated technology than before the probability of type 2 diabetic patients on glibenclamide to experience hypoglycemic episodes will be registered. Hypoglycemia is prone to cardiovascular complications in type 2 diabetic patients due to concomitant dysregulation of blood flow. With standardized test meals followed by exercise in a clinical setting hormonal counterregulation and cardiovascular parameters associated with hypoglycemia will be identified. The acute effect of different conditions of exercise and a single dose of either glibenclamide or placebo will be followed each day during the total three-day observation period. Thus we will evaluate the frequency of and the risk factors associated with hypoglycemia and meal-related hyperglycemia in type 2 diabetic patients.

Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes on glibenclamide with or without
* Glycated hemoglobin ≤ 7.5%
* Stable dosage for three weeks

Exclusion Criteria:

* HbA1c \> 7.5%
* Fasting C-peptide below normal
* Concurrent infectious disease
* Pregnancy
* Malignant disease
* Inability to give informed consent

Primary outcomes:
measure: Number of hypoglycemic events
timeFrame: 3 days
Secondary outcomes:
measure: Secretion of hormones increasing blood glucose, effect of exercise on hypoglycemic events, postprandial glucose excursions, heart rate and forearm blood flow at hypoglycemia
timeFrame: 3 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02337569: A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency
Official title: A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Zinc Deficiency
Lead sponsor: Nobelpharma
Sponsor class: INDUSTRY
First posted: 2015-01-13
Enrollment: 57
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate efficacy and safety of NPC-02 in patients with Zinc Deficiency.


Eligibility criteria: Inclusion Criteria:

The serum zinc concentrations are under the normal level before registration

Exclusion Criteria:

1. Heavy hepatitis
2. Malignant tumor
3. Severe heart disease, hematological disorder, kidney disease and pancreatic disease, etc.
4. The serum albumin under 2.8 g/dL
5. Patient of allergy and hyperesthesia to zinc containing medicine manufacturing (including supplement)
6. Patient who was taking a medicine including the zinc (including supplement) within 12 weeks before registration
7. Pregnant, suspected pregnant, lactating, patients who wish to have a child
8. Patient who participated in other clinical trials within 12 weeks before registration
9. Unsuitable as a target of this clinical trial judged by doctor

Primary outcomes:
measure: The change amount of serum zinc concentration between starting and 8 weeks after dosing
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Osaka
country: Japan
facility: Osaka Medical Center for Cancer and Cardiovascular Diseases
Study officials:
References:
citation: Katayama K, Hosui A, Sakai Y, Itou M, Matsuzaki Y, Takamori Y, Hosho K, Tsuru T, Takikawa Y, Michitaka K, Ogawa E, Miyoshi Y, Ito T, Ida S, Hamada I, Miyoshi K, Kodama H, Takehara T. Effects of Zinc Acetate on Serum Zinc Concentrations in Chronic Liver Diseases: a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial and a Dose Adjustment Trial. Biol Trace Elem Res. 2020 May;195(1):71-81. doi: 10.1007/s12011-019-01851-y. Epub 2019 Aug 7.
Clinical trial NCT00603369: HIV, Abuse, and Psychiatric Disorders Among Youth
Official title: HIV, Abuse, and Psychiatric Disorders Among Youth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HIV Infections
Keywords: HIV prevention
HIV seronegativity
Lead sponsor: Rhode Island Hospital
Sponsor class: OTHER
First posted: 2008-01-29
Enrollment: 212
Sex: ALL
Minimum age (years): 13
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: One subgroup of adolescents at particular risk for HIV is those with psychiatric disorders. Furthermore, those with histories of sexual abuse have been found to have riskier attitudes, poorer sexual communication skills, and less consistent condom use than non-abused peers. This study implemented and evaluated interventions for adolescents in intensive psychiatric treatment settings, particularly those with histories of sexual abuse. It is hypothesized that those participating in the intervention that addresses affect management and cognitive monitoring strategies will show fewer HIV-risk related behaviors and attitudes at posttest than peers in an information-based intervention.


Eligibility criteria: Inclusion Criteria:

* Adolescent attending therapeutic school

Exclusion Criteria:

* Adolescent is HIV positive
* Adolescent is developmentally delayed
* Adolescent is pregnant
* Adolescent has a history of sexual crime

Primary outcomes:
measure: condom use
timeFrame: 1 year
Secondary outcomes:
measure: scores on HIV knowledge questionnaire
timeFrame: 1 year
measure: number of sexual partners
timeFrame: 1 year
measure: scores on measure of attitudes toward condom use
timeFrame: 1 year
Other outcomes:
Locations:
city: Providence
country: United States
facility: Rhode Island Hospital
state: Rhode Island
Study officials:
affiliation: Rhode Island Hospital
name: Larry K. Brown, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Brown LK, Nugent NR, Houck CD, Lescano CM, Whiteley LB, Barker D, Viau L, Zlotnick C. Safe Thinking and Affect Regulation (STAR): human immunodeficiency virus prevention in alternative/therapeutic schools. J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):1065-74. doi: 10.1016/j.jaac.2011.06.018. Epub 2011 Aug 27.
Clinical trial NCT03649269: PC-300 Tea Effect on Triglyceride Levels
Official title: Eryngium Heterophyllum + Amphipterygium Adstringens Tea Effect on Triglyceride Levels
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertriglyceridemia
Keywords: Eryngium heterophyllum
Amphipterygium adstringens
tea
Lead sponsor: Ciprés Grupo Médico CGM SC
Sponsor class: OTHER
First posted: 2018-08-28
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Voluntary subjects were assigned sequentially into two treatment groups: 1) fibrate (bezafibrate) 200 mg/day, and 2) PC-300 tea, one cup half an hour before eating.
Primary purpose: TREATMENT

Brief summary: Herbal medicine represents an alternative for treating dyslipidemia. The aim of this project was to evaluate the PC-300 tea (Eryngium heterophyllum egelm + Amphipterygium adstringens) against hypertriglyceridemia.

Baseline samples of serum total cholesterol and triglycerides were obtained and measured again after 1 month of treatment with the following two alternatives: 1) PC-300, one cup half an hour before eating, and 2) bezafibrate 200 mg/d.

Detailed description: It was a descriptive, prospective, longitudinal, and comparative clinical study developed at Ciprés Grupo Médico S.C. (CGM), Toluca, Mexico, from January 2014 to December 2014.

Patients with hypertriglyceridemia were invited to participate in the study. Voluntary subjects were assigned sequentially into two treatment groups: 1) fibrate (bezafibrate) 200 mg/day, and 2) PC-300 tea, one cup half an hour before eating.

Patients were measured (m) and weighed (kg) (Obi, México). Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Blood pressure was measured with a calibrated sphygmomanometer (Welch Allyn, USA) after 5 min of rest.

All of the patients were given a low lipid diet. Calculated kcal were based on ideal weight minus 200 kcal/day if overweight.

Results were expressed as mean ± Standard deviation (SD). Differences between initial vs. final values were compared with the Mann-Whitney U test. The normality hypothesis was tested using the Kolmogorov-Smirnov test. A p value of \<0.05 was considered significant. All tests were performed with the SPSS ver. 23 statistical software program.

Eligibility criteria: Inclusion Criteria:

* Patients with hypertriglyceridemia, aged \>18 years and with an educational level at least of primary school.

Exclusion Criteria:

* Patients with hepatic disease and those missing an appointment during the study.

Primary outcomes:
measure: Triglycerides serum levels.
timeFrame: One month.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Ciprés Grupo Médico
name: Hugo Mendieta Zerón, PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05152069: Spatio-temporal Parameters of Walking in Patients Hospitalized in Acute Geriatrics
Official title: Spatio-temporal Parameters of Walking in Patients Hospitalized in Acute Geriatrics: Comparison of a Population of Fallers and Non-fallers
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Difficulty Walking
Keywords: Difficulty Walking
Elderly person
Spatio-temporal parameters
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2021-12-09
Enrollment: 67
Sex: ALL
Minimum age (years): 71
Standard ages: OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subject aged \> 70 years have been hospitalized in an acute geriatric ward at the University Hospitals of Strasbourg between 01/06/2019 and 28/02/2020 and ave been able to walk on a square surface at least 12 meters long, with or without technical assistance

Brief summary: The prevalence of walking disorders in the elderly is high. These can lead to falls which represent a major public health issue in terms of hospitalization, morbidity and cost. Numerous studies analyzing the link between spatio-temporal parameters of gait and fall have already been carried out, but most have been carried out in a population of elderly patients living at home and having no or few comorbidities. Very few studies have been carried out in a population of frail elderly people, with multiple comorbidities or multiple medication, which is the case with most patients hospitalized in acute geriatrics.

The objective of the study is to evaluate the spatio-temporal parameters of walking using the GAITRite® mat in patients hospitalized in acute geriatrics and to compare them between a population of falling patients and a population of patients. no faller.


Eligibility criteria: Inclusion criteria:

* Subject aged \> 70 years
* Have been hospitalized in an acute geriatric ward at the University Hospitals of Strasbourg between 01/06/2019 and 28/02/2020
* Have been able to walk on a square surface at least 12 meters long, with or without technical assistance
* Subject not having expressed, after being informed, his opposition to the reuse of his medical data for scientific research purposes.

Exclusion criteria:

* Subject having expressed opposition to participating in the study
* Non-autonomous subject for transfers and trips
* Subject under guardianship, curatorship or safeguard of justice

Primary outcomes:
measure: Study of the spatio-temporal parameters of walking using the GAITRite® mat in patients hospitalized in acute geriatrics and to compare them between a population of falling patients and a population of patients. no faller.
timeFrame: Files analysed retrospectively from June 1, 2019 to February 28, 2020 will be examined]
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Gériatrie Aigue - Hôpitaux Universitaires de Strasbourg
Study officials:
References: